Incanthera has developed a ‘smart bomb’ therapy which selectively targets solid tumours without harming healthy cells, meaning virtually no side effects to the rest of the body. Incanthera has recently acquired University of Salford anticancer drug discovery spin-out Onco-NX Ltd.

Onco-NX has been developing a promising bio reductive agent called ‘Es5’ which is at the pre-clinical development stage and is a pro- drug selectively activated by enzymes overexpressed in tumours. Merging these 2 companies has greatly increased the value of both in terms of shared management teams and experience and is the beginning of a pipeline of opportunities for Incanthera.